From mechanism to resistance – changes in the use of dexamethasone in the treatment of multiple myeloma
Author:
Affiliation:
1. UC Davis Comprehensive Cancer Center, Sacramento, CA, USA
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2136950
Reference51 articles.
1. Treatment of relapsed and refractory multiple myeloma
2. A pharmacodynamic model of clinical synergy in multiple myeloma
3. Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
4. Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
5. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy;Frontiers in Molecular Medicine;2024-09-06
2. Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature;International Journal of Cancer;2024-06-14
3. Multiple Myeloma;Home Healthcare Now;2024-05
4. Aponermin: First Approval;Drugs;2024-03-05
5. Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews;Frontiers in Oncology;2022-12-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3